In Crescentic IgA Nephropathy, Fractional Excretion of IgG in Combination with Nephron Loss Is the Best Predictor of Progression and Responsiveness to Immunosuppression

被引:25
作者
Bazzi, Claudio [1 ]
Rizza, Virginia [2 ]
Raimondi, Sara [4 ]
Casellato, Daniela [3 ]
Napodano, Pietro [3 ]
D'Amico, Giuseppe [1 ]
机构
[1] San Carlo Borromeo Hosp, Fdn Amico Ric Malattie Renali, I-20100 Milan, Italy
[2] San Carlo Borromeo Hosp, Biochem Lab, I-20100 Milan, Italy
[3] San Carlo Borromeo Hosp, Nephrol & Dialysis Unit, I-20100 Milan, Italy
[4] European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2009年 / 4卷 / 05期
关键词
PROXIMAL TUBULAR CELLS; MEMBRANOUS NEPHROPATHY; NATURAL-HISTORY; CYCLOPHOSPHAMIDE; PROTEIN; THERAPY; DISEASE;
D O I
10.2215/CJN.05711108
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: The aim of this study was to evaluate the relationship between proteinuric markers (urinary excretion of IgG, alpha 2-macroglobulin, alpha 1-microglobulin) and serum creatinine (sCr), histologic lesions, progression, and immunosuppression responsiveness in crescentic IgA nephropathy. Design, setting, participants, & measurements: Fractional excretion of IgG (FEIgG) and of alpha 1-microglobulin and urinary excretion of alpha 2-macroglobulin were evaluated in 37 patients, 23 treated with steroids and cyclophosphamide. For assessment of the effective tubular load of proteins in surviving nephrons, new markers that take into account not only the absolute excretion value but also nephron loss were obtained dividing proteinuric markers for percentage of nonobsolescent glomeruli (surviving glomeruli [SG]). For each parameter, low- and high-risk groups were defined according to cutoffs with the highest sensitivity and specificity for progression (ESRD/doubling sCr) assessed by receiver operating characteristic analysis; follow up was 60 +/- 40 mo. Results: FEIgG/SG is the most powerful progression predictor: 5 versus 83% in all patients; in treated patients, 0 versus 89%, increased to 0 versus 100% by sCr and FEIgG/SG in combination (low risk: both markers or only one below cutoff (n = 15); high risk: both markers above cutoff (n = 8). The nonprogressors showed at last observation 65% proteinuria reduction and 10%, sCr reduction. Conclusions: In crescentic IgA nephropathy, FEIgG/SG, which evaluates altered size selectivity in relation to nephron loss, is the best progression predictor. In treated patients, progression prediction was increased by FEIgG/SG and sCr in combination. Treatment may be restricted to low-risk patients. Clin Am Soc Nephrol 4: 929-935, 2009. doi: 10.2215/CJN.05711108
引用
收藏
页码:929 / 935
页数:7
相关论文
共 20 条
[11]  
Harper L, 2000, J NEPHROL, V13, P360
[12]  
McIntyre CW, 2001, CLIN NEPHROL, V56, P193
[13]   Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy [J].
Mezzano, SA ;
Droguett, MA ;
Burgos, ME ;
Ardiles, LG ;
Aros, CA ;
Caorsi, I ;
Egido, J .
KIDNEY INTERNATIONAL, 2000, 57 (01) :147-158
[14]   Steroid and cyclophosphamide in IgA nephropathy [J].
Roccatello, D ;
Ferro, M ;
Cesano, G ;
Rossi, D ;
Berutti, S ;
Salomone, M ;
Piccoli, G ;
Sena, LM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2000, 15 (06) :833-835
[15]  
ROCCATELLO D, 1995, NEPHROL DIAL TRANSPL, V10, P2054
[16]   Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy [J].
Tumlin, JA ;
Hennigar, RA .
SEMINARS IN NEPHROLOGY, 2004, 24 (03) :256-268
[17]   Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide [J].
Tumlin, JA ;
Lohavichan, V ;
Hennigar, R .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (07) :1321-1329
[18]  
Wang YP, 1997, J AM SOC NEPHROL, V8, P1537
[19]   Protein overload stimulates RANTES production by proximal tubular cells depending on NF-KB activation [J].
Zoja, C ;
Donadelli, R ;
Colleoni, S ;
Figliuzzi, M ;
Bonazzola, S ;
Morigi, M ;
Remuzzi, G .
KIDNEY INTERNATIONAL, 1998, 53 (06) :1608-1615
[20]  
ZWEIG MH, 1993, CLIN CHEM, V39, P561